폐암 치료제 시장 보고서 : 치료법, 암 유형, 유통 채널, 지역별(2026-2034년)

The global lung cancer therapeutics market size reached USD 36,081.6 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 76,308.4 Million by 2034, exhibiting a growth rate (CAGR) of 8.42% during 2026-2034. The market is experiencing steady growth driven by the rapid increase in the incidence of lung cancer, which is aggravated by smoking and environmental pollution around the world, the further development of individualized treatment, including based on the gene profile, and the continuous advancement of technology for diagnosing the disease, to ensure early detection of the pathology.

LUNG CANCER THERAPEUTICS MARKET ANALYSIS:

• Major Market Drivers: The massive prevalence and mortality associated with lung cancer worldwide is creating a high lung cancer therapeutics market demand.
• Key Market Trends: The market will develop in the direction of personalized medicine as an increasing number of therapies addressing particular genetic mutations in tumor cells are created. Additionally, the incorporation of AI and machine learning in the diagnostic processes enhancing the chances and precision of accessing such treatments is acting as one of the major lung cancer therapeutics market trends.
• Geographical Trends: The market analysis states that North America leads the market regarding lung cancer therapeutics due to the robust healthcare structures, health expenditures, and early use of advanced oncology treatments. Asia Pacific region, including China and India, is driving the market based on rapidly growing healthcare awareness and improved healthcare delivery systems.
• Competitive Landscape: According to the lung cancer therapeutics market overview, the market is highly competitive based on the existence of well-established pharmaceutical giants and new emerging biofirms. Additionally, major companies are innovating and expanding their product lines through research and development and partnerships.
• Challenges and Opportunities: The high cost of new cancer medicines emerges as the main challenge to the lung cancer therapeutics revelations to the low- and middle-income economies, creating accessibility gaps. However, such challenges amplify as lung cancer therapeutics market recent opportunities for developing cost-effective generics and biosimilars.

LUNG CANCER THERAPEUTICS MARKET TRENDS:

Rising incidence of lung cancer worldwide

Another factor contributing to the lung cancer therapeutics market growth is the increasing incidence of lung cancer. The American Cancer Society made an estimation of lung cancer in the US by 2024. The number of new cancer occurrences should approximately equal 234,580 individuals, including 116,310 males and 118,270 females. The number of deaths will equal 125,070 deaths, which involves 65,790 male deaths and 59,280 female deaths. This can be supported by the exponentially growing global population and the prevalence of harmful factors causing lung cancer such as smoking, air and environmental pollution, and harmful workplace events. Thus, this is also influencing the lung cancer therapeutics market statistics. Due to the constantly increasing incidence of lung cancer, more active measures are needed. Accordingly, the development and improvement of methods, including drugs, for lung cancer treatment are constantly developing. Increased supply creates more reason for pharmaceutical companies to conduct tests and develop new ones and expand their assortment. Accordingly, demand for more effective drugs is growing. Thus, lung cancer therapeutics is the fastest-growing.

Innovations in personalized medicine

The lung cancer therapeutics market growth is increasing significantly with the development of personalized medicine, which treats each patient based on genetic features. In recent years, the drug industry has developed and produced drugs that precisely attack such mutations. These have proven to be more effective than chemotherapy, causing fewer side effects. The lung cancer therapeutics market forecast suggests that personalized medicine will become the basis of therapy for this oncology; this means an increase in the efficiency of therapy since the prescription will be more accurate. Furthermore, the growing emphasis on precision medicine is fueled by technological progress in diagnostics and an increased understanding of genetic factors influencing lung cancer progression. Consequently, the pharmaceutical industry's investment in personalized solutions continues to expand, aligning drug development with specific patient needs and substantially driving the lung cancer therapeutics market forward.

Continuous advancements in diagnostics and treatment

Technological innovations drive the market, particularly in diagnostics and treatment delivery. In addition, improved imaging and AI-assisted diagnostic tools allow lung cancer detection early and more accurately. Along with this, this notion is a game-changer for treatment efficacy and patient recovery. Apart from this, the lung cancer therapeutics market recent developments include the introduction of new and developing minimally invasive surgery techniques, enhanced radiation treatment approaches, and advanced drug-delivery systems, including nanoparticle-based chemo preparations. In addition, the accuracy and effectiveness of advanced technology cannot imagine a comfortable treatment and recoverable patient view. Furthermore, the combination of all these technologies is creating a positive market outlook.

LUNG CANCER THERAPEUTICS MARKET SEGMENTATION:

Breakup by Therapy:

• Targeted Therapy
  • Bevacizumab
  • Dabrafenib/Trametinib
  • Erlotinib Hydrochloride
  • Osimertinib
  • Others
• Immunotherapy
  • Durvalumab
  • Nivolumab
  • Atezolizumab
  • Pembrolizumab
• Radiation Therapy
  • External Beam
  • Internal Beam
  • Systemic
• Chemotherapy

Targeted therapy accounts for the majority of the market share

The therapy segment is the largest as it is more efficient and has fewer side effects compared to traditional chemotherapy. It includes drugs or other materials that can accurately recognize and kill cancer cells. This treatment is probably directed at the molecular and genetic features that differentiate cancer cells from others. In addition, the current level of understanding of genetic aspects of lung cancer allows the identification of many specific molecular targets and, correspondingly, agents that can prevent the activation of these targets. According to the lung cancer therapeutics market forecast, the development of molecular biology and genetics will consistently increase the number of targets and agents that could be used to combat the described disease. Hence, it is reasonable to suppose that the targeted therapy segment will continue developing due to the appearance of new potential targets and agents.

Breakup by Cancer Type:

• Non-Small Cell Lung Cancer (NSCLC)
• Small Cell Lung Cancer (SCLC)

Non-Small Cell Lung Cancer (NSCLC) holds the largest share of the industry

The non-small cell lung cancer segment holds the largest share in the market due to its high prevalence. Individually, the subtypes share pathological variations, but they progress more slowly than small-cell lung cancer. As such, the high global prevalence of NSCLC creates a sizable lung cancer therapeutics market demand for the different subtypes, thereby incentivizing pharmaceutical companies and researchers to focus on developing therapies and immunotherapies that can treat the subtype gene and molecular distinctions effectively. In addition, the changing molecular pathogenesis capacity for NSCLC also ensures that the development of precision medicine causes NSCLC to have a correlation with the market.

Breakup by Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other

Hospital pharmacies represents the leading market segment

Hospital pharmacies are the largest channel of distribution in the lung cancer therapeutics segment due to the complicated and advanced nature of the therapies for the disease. Doctors require a controlled environment to administer treatments, including chemotherapy solutions, which need to be carefully regulated to avoid side effects. According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies According to the lung cancer therapeutics market analysis, most lung cancer therapies are for inpatients given the need for complex therapies such as chemotherapy, targeted therapy, and immunotherapies. Additionally, hospital pharmacies are critical in facilitating integrated lung cancer care as the patient can access all the required treatments immediately and from the same hospital that can coordinate oncology, surgery, and radiology departments. Apart from this, the centralization of centrality ensures the patient undergoes therapy with minimal delays which improves the effectiveness of the therapeutics. Furthermore, the demand for infrastructure and personnel expertise is increasing the lung cancer therapeutics market revenue.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America leads the market, accounting for the largest lung cancer therapeutics market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America represents the largest regional market for lung cancer therapeutics.

North America has the largest regional lung cancer therapeutics market share due to high disease prevalence, advanced healthcare infrastructure, and one of the highest healthcare spender factors. Along with this, high government contribution and private sector support in the US and Eurozone countries, spent on research and development, also play a key role in the growth of the North American market. Furthermore, the accelerating investments to develop technologies and initiatives to diagnose and treat lung cancer are influencing lung cancer therapeutics market revenue positively. As the lung cancer therapeutics market growth trend shows, in the past decade, various targeted therapies and immunotherapies have been developed and used in the treatment of lung cancer. Furthermore, the regulatory environment across the region also has a friendly policy of fast-track cancer drugs. Moreover, the high levels of patient awareness across the region, and insurance coverage ensures North America continues to dictate the global market.

COMPETITIVE LANDSCAPE:

The market research report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the lung cancer therapeutics industry include:

• AbbVie Inc.
• Amgen Inc.
• AstraZeneca Plc
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company Limited
• Eli Lilly and Company
• GSK PLC
• Merck & Co. Inc.
• Novartis AG
• Pfizer Inc.
• Roche Holding AG
• Takeda Pharmaceutical Company Limited

The major lung cancer therapeutics market companies swiftly develop their product portfolios. As R&D remains critically important in their aim to expand, these companies, Roche, Pfizer, AstraZeneca, and other influential giants, are recognized as the most innovative pharmaceutical firms globally. In particular, they are developing targeted therapy and immunotherapy, which showed encouraging outcomes in addressing numerous lung cancer subtypes. Therefore, this is acting as one of the major market trends. In addition, the companies invest in advanced clinical trials to develop new indication opportunities, significantly expanding the imaginable market for their products. Furthermore, the M&A activity is also very high in the industry where several companies attempt to purchase all competitors and utilize all the latest technology available on the market. Thus, the need to stay competitive in the market for therapeutic results and improved patient outcomes.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How has the global lung cancer therapeutics market performed so far, and how will it perform in the coming years?
• What are the drivers, restraints, and opportunities in the global lung cancer therapeutics market?
• What is the impact of each driver, restraint, and opportunity on the global lung cancer therapeutics market?
• What are the key regional markets?
• Which countries represent the most attractive lung cancer therapeutics market?
• What is the breakup of the market based on the therapy?
• Which is the most attractive therapy in the lung cancer therapeutics market?
• What is the breakup of the market based on the cancer type?
• Which is the most attractive cancer type in the lung cancer therapeutics market?
• What is the breakup of the market based on the distribution channel?
• Which is the most attractive distribution channel in the lung cancer therapeutics market?
• What is the competitive structure of the market?
• Who are the key players/companies in the global lung cancer therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Lung Cancer Therapeutics Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Therapy

• 6.1 Targeted Therapy
  • 6.1.1 Market Trends
  • 6.1.2 Key Segments
    • 6.1.2.1 Bevacizumab
    • 6.1.2.2 Dabrafenib/Trametinib
    • 6.1.2.3 Erlotinib Hydrochloride
    • 6.1.2.4 Osimertinib
    • 6.1.2.4 Others
  • 6.1.2 Market Forecast
• 6.2 Immunotherapy
  • 6.2.1 Market Trends
  • 6.2.2 Key Segments
    • 6.2.2.1 Durvalumab
    • 6.2.2.2 Nivolumab
    • 6.2.2.3 Atezolizumab
    • 6.2.2.4 Pembrolizumab
  • 6.2.2 Market Forecast
• 6.3 Radiation Therapy
  • 6.3.1 Market Trends
  • 6.3.2 Key Segment
    • 6.3.2.1 External Beam
    • 6.3.2.2 Internal Beam
    • 6.3.2.3 Systemic
  • 6.3.2 Market Forecast
• 6.4 Chemotherapy
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Cancer Type

• 7.1 Non-small Cell Lung Cancer (NSCLC)
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Small Cell Lung Cancer (SCLC)
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast

8 Market Breakup by Distribution Channel

• 8.1 Hospital Pharmacies
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Retail Pharmacies
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Online Pharmacies
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast
• 8.4 Others
  • 8.4.1 Market Trends
  • 8.4.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

• 10.1 Overview
• 10.2 Drivers
• 10.3 Restraints
• 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 AbbVie Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Amgen Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 AstraZeneca Plc
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Boehringer Ingelheim International GmbH
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
  • 14.3.5 Bristol-Myers Squibb Company
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
  • 14.3.6 Daiichi Sankyo Company Limited
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
  • 14.3.7 Eli Lilly and Company
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
  • 14.3.8 GSK PLC
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Merck & Co. Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Novartis AG
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 Pfizer Inc.
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
  • 14.3.12 Roche Holding AG
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
  • 14.3.13 Takeda Pharmaceutical Company Limited
    • 14.3.13.1 Company Overview
    • 14.3.13.2 Product Portfolio